Patterns of Medication Prescriptions for Diabetes Mellitus Type 2 in Five Departments of Colombia in 2014

Authors

  • Noël C. Barengo Organization for Health Excellence, Florida International University https://orcid.org/0000-0003-0660-3091
  • Sandra Camacho Organization for Health Excellence
  • Pilar Andrea López Organization for Health Excellence
  • Paul Anthony Camacho Santander Ophthalmology Foundation
  • Ángel Alberto García San Ignacio University Hospital, Pontifical Xavierian University
  • Jaime Alejandro Hincapié Clínica Integral de Diabetes
  • Alexander Maceneth Centro Médico Oftalmológico
  • Patricio López Jaramillo Santander Ophthalmology Foundation

DOI:

https://doi.org/10.17533/udea.rfnsp.v36n2a08

Keywords:

primary health care, diabetes mellitus type 2, medicine prescription, Colombia

Abstract

Objective: to describe the patterns of medication prescriptions for diabetes mellitus type 2 (DM2) and the comorbidity of patients treated in five health care institutions in Colombia. Methodology: descriptive cross-sectional study carried out checking the medical records of 5098 patients with DM2 treated at the outpatient service centers in five Colombian cities between January 1 and December 31 of 2014. Each patient with DM2 had a record of at least two outpatient appointments registered during the time of this study. The information was collected through electronic surveys. National and international guidelines on diabetes treatment were used to categorize the medications. The SPSS® 21 software was used to analyze the data.
Results: the most frequently prescribed medications were biguanides (59%) and sulfonylureas (28%). The prescription of inhibitors for Dipeptidyl peptidase-4 was 7% and the frequency of prescription of glucagon-like peptide-1 receptor agonists (AR GLP-1) was 2%. The medication with the highest frequency of prescription as monotherapy were biguanides (22%). The most frequent combination was biguanide and sulfonylureas (21%). The second most frequent combination was biguanide with insulin (10%), and other combinations. 27% of patients with DM2 did not receive any pharmacological treatment for diabetes.
Regarding the medicines for comorbidity, 52% of patients use at least one type of antihypertensive drug, 39% use at least one type of hypolipidemic drug and 35% uses acetylsalicylic acid. Conclusions: biguanides were the most frequently prescribed medication, sulfonylureas came after. One in four patients did not have a record of medicine prescription. The prescription of acetylsalicylic acid to prevent cardiovascular risk was lower than expected.
|Abstract
= 685 veces | PDF (ESPAÑOL (ESPAÑA))
= 322 veces|

Downloads

Download data is not yet available.

Author Biographies

Noël C. Barengo, Organization for Health Excellence, Florida International University

Organization for Health Excellence, Bogotá, Colombia. Herbert Wertheim College of Medicine, Florida International University, United States.

Sandra Camacho, Organization for Health Excellence

Organization for Health Excellence, Bogotá, Colombia. 

Pilar Andrea López, Organization for Health Excellence

Organization for Health Excellence, Bogotá, Colombia.

Paul Anthony Camacho, Santander Ophthalmology Foundation

Santander Ophthalmology Foundation, Bucaramanga, Colombia.

Ángel Alberto García, San Ignacio University Hospital, Pontifical Xavierian University

San Ignacio University Hospital, Pontifical Xavierian University. Bogotá, Colombia.

Jaime Alejandro Hincapié, Clínica Integral de Diabetes

Clínica Integral de Diabetes, Medellin, Colombia.

Alexander Maceneth, Centro Médico Oftalmológico

Centro Médico Oftalmológico, Ibagué, Colombia.

Patricio López Jaramillo, Santander Ophthalmology Foundation

Santander Ophthalmology Foundation, Bucaramanga, Colombia.

References

(1). International Federation of Diabetes. IDF diabetes atlas. 7.a ed. Bruselas: IDF; 2015. p. 15.

(2). Aschner P. Epidemiología de la diabetes en Colombia. Av. Diabetol. 2010;26(2):95-100.

(3). Villegas-Perrasse A, Abad S, Faciolince S, Hernández N, Maya C, Parra L, et al. El control de la diabetes mellitus y sus complicaciones en Medellín, Colombia, 2001-2003. Rev. Panam. Salud Pública. 2006;20(6):393-402.

(4). Machado-Alba J, Moncada-Escobar J, Mesa-Escobar G. Patrones de prescripción de antidiabéticos en un grupo de pacientes colombianos. Rev. Panam. Salud Pública. 2007;22(2):124-31.

(5). Machado-Alba J, Moncada-Escobar J, Gaviria H. Quality and effectiveness of diabetes care for a group of patients in Colombia. Rev. Panam. Salud Pública. 2009;26(6):529-35.

(6). Mejía S, Vélez A, Buriticá O, Arango M, Río J del. La política farmacéutica nacional en Colombia y la reforma de la seguridad social: acceso y uso racional de medicamentos. Cad. Saúde Pública 2002;18(4):1025-39.

(7). American Diabetes Association. Pharmacologic approaches to glycemic treatment. Diabetes Care 2017;40(Suppl. 1):S64-S74.

(8). Aschner P, Muñoz V, Girón D, García O, Fernández-Ávila D, Casas L, et al. Guía de práctica clínica para la prevención, diagnóstico, tratamiento y seguimiento de la diabetes mellitus tipo 2 en la población mayor de 18 años. Colombia Médica 2016;47(2):109-31.

(9). Colombia, Ministerio de Salud y Protección Social. Resolución 8430 de 1993. Por la cual se establecen las normas científicas, técnicas y administrativas para la investigación en salud. [Internet] 1993 [Consultado 10 de agosto de 2014]. Disponible en: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/DE/DIJ/RESOLUCION-8430-DE-1993.PDF

(10). Colombia, Ministerio de la Protección Social. Encuesta Nacional de Salud (ENS) 2007. [Internet] 2009 [Consultado 10 de agosto de 2014]. Disponible en: https://www.minsalud.gov.co/Documentos%20y%20Publicaciones/ENCUESTA%20NACIONAL.pdf

(11). Colombia, Ministerio de Salud y Proteccion Social. Guía de práctica clínica para el diagnóstico, tratamiento y seguimiento de la diabetes mellitus tipo 2 en la poblacion mayor de de 18 años. Bogota: Alianza CINETS. [Internet] 2015. [Consultado 10 de agosto de 2014]. Disponible en: http://gpc.minsalud.gov.co/gpc_sites/Repositorio/Conv_637/GPC_diabetes/DIABETES_TIPO_2_COMPLETA.pdf

(12). Guzmán JR, Lyra R, Aguilar-Salinas CA, Cavalcanti S, Escaño F, Tambasia M, et al. Treatment of type 2 diabetes in Latin America: A consensus statement by the medical associations of 17 Latin American countries. Rev. Panam. Salud Pública. 2010;28(6):463-71.

(13). American Diabetes Association. Standards of medical care in diabetes 2016. Diabetes Care 2016;39(Suppl. 1): S1-112.

(14). Lopez-Stewart G, Tambascia M, Rosas Guzmán J, Etchegoyen F, Ortega-Carrión J, Artemenko S. Control of type 2 diabetes mellitus among general practitioners in nine countries of Latin America. Rev. Panam. Salud Pública. 2007;22(1):12-20.

(15). Gagliardino JJ, Hera M de la, Siri F y Grupo de Investigación de la Red QUALIDIAB. Evaluación de la calidad de la asistencia al paciente diabético en América Latina. Rev. Panam. Salud Pública 2001;10(5):309-17.

(16). Gómez-García A, Soto-Paniagua JC, Álvarez-Aguilar C. Uso de hipoglucemiantes orales en pacientes con diabetes mellitus tipo 2. Aten. Primaria 2005;35(7):348-52.

(17). Antithrombotic Trialists' (ATT) Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, et al. Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373(9678):1849-60.

(18). Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur. Heart J. 2012;33(13):1635-701.

(19). Huxley RR, Peters SA, Mishra GD, Woodward M. Risk of all-cause mortality and vascular events in women versus men with type 1 diabetes: A systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2015;3(3):198-206.

(20). Peters SA, Huxley RR, Woodward M. Diabetes as risk factor for incident coronary heart disease in women compared with men: A systematic review and meta-analysis of 64 cohorts including 858,507 individuals and 28,203 coronary events. Diabetologia. 2014;57(8):1542-51.

(21). Kalyani RR, Lazo M, Ouyang P, Turkbey E, Chevalier K, Brancati F, et al. Sex differences in diabetes and risk of incident coronary artery disease in healthy young and middle-aged adults. Diabetes Care. 2014;37(3):830-8.

(22). Peters SA, Huxley RR, Woodward M. Diabetes as a risk factor for stroke in women compared with men: A systematic review and meta-analysis of 64 cohorts, including 775,385 individuals and 12,539 strokes. Lancet 2014;383(9933):1973-80.

Downloads

Published

2018-06-08

How to Cite

1.
Barengo NC, Camacho S, López PA, Camacho PA, García Ángel A, Hincapié JA, Maceneth A, López Jaramillo P. Patterns of Medication Prescriptions for Diabetes Mellitus Type 2 in Five Departments of Colombia in 2014. Rev. Fac. Nac. Salud Pública [Internet]. 2018 Jun. 8 [cited 2025 Feb. 23];36(2):58-65. Available from: https://revistas.udea.edu.co/index.php/fnsp/article/view/327719

Issue

Vol. 36 No. 2 (2018): Mayo-Agosto

Section

Servicios de salud

License

The contents of the articles are the responsibility of the authors

The editorial committee has editorial independence from the National School of Public Health "Héctor Abad Gómez" of the University of Antioquia.

The editorial committee is not responsible for aspects related to copying, plagiarism or fraud that may appear in the articles published in it.

When you are going to reproduce and disclose photographs or personal data in printed or digital format, informed consent is required. Therefore, this requirement is required of the author at the time of receipt of the manuscript.

Authors are responsible for obtaining the necessary permissions to reproduce any material protected by reproduction rights.

The authors preserve the moral rights and assign the economic rights that will correspond to the University of Antioquia, to publish it, distribute electronic copies, include them in indexing services, directories or national and international databases in Open Access, under the Creative Commons Attribution license -Not Commercial-Share Equal 4.0 International Commercial (CC BY-NC-SA) which allows others to distribute, remix, retouch, and create from the work in a non-commercial way, as long as the respective credit and license are granted. new creations under the same conditions.

The authors will sign the declaration of transfer of economic rights to the University of Antioquia, after the acceptance of the manuscript.

The editorial committee reserves the right to reject the articles whose authors do not offer satisfactory explanations about the contribution of each author, to meet the criteria of authorship in the submission letter. All authors must meet the four criteria of authorship according to ICMJE: "a) .- That there is a substantial contribution to the conception or design of the article or to the acquisition, analysis or interpretation of the data. b) That they have participated in the design of the research work or in the critical review of its intellectual content. c) .- That has been intervened in the approval of the final version that will be published.d). That they have the capacity to respond to all aspects of the article in order to ensure that issues related to the accuracy or integrity of any part of the work are adequately investigated and resolved. "

Crossref
Scopus
Google Scholar
Europe PMC

Most read articles by the same author(s)